Keyword: Rubraca

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.

Clovis' stock is down on a disappointing performance from its sole product, the PARP inhibitor Rubraca. That could make Clovis a target of M&A talk.

GSK’s Zejula has opened up a new front in its challenge against AstraZeneca and Merck’s Lynparza, the established leader in the PARP class.

Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.

Despite the FDA's breakthrough therapy designation for Zejula in prostate cancer, J&J will face a tough rival in Lynparza from AstraZeneca and Merck.

Strong data from GSK's Zejula and AstraZeneca and Merck's Lynparza are "incrementally negative to" Clovis Oncology's PARP inhibitor Rubraca, analysts say.

AZ and Merck’s Lynparza is ahead of rival PARP inhibitors—but not comfortably ahead. That may change, though, thanks to key clinical trial news.

Results from a phase 3 trial of Merck and AstraZeneca's PARP inhibitor Lynparza in prostate cancer could give them a leg up on rivals.

It’s no secret that Clovis Oncology is up against some serious marketing muscle. And investors are doubting the company’s ability to hang in there.

Clovis Oncology's PARP inhibitor Rubraca didn't spur enough response to warrant continuing a phase 2 bladder cancer study.